ustekinumab, Stelara

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC NAME: ustekinumab


DRUG CLASS AND MECHANISM: Ustekinumab is an injectable biologic drug that suppresses the immune system and is used for the treatment of psoriasis. It is an antibody that binds to interleukin (IL)-12 and IL-23, two chemicals produced by cells in the body that stimulate immune reactions. Scientists believe that psoriasis is caused by an increase in the production of T-lymphocytes in response to the attachment of a stimulant, such as interleukin, to the lymphocyte. Stimulated T-lymphocytes cause skin cells to grow rapidly, and the rapid growth of the skin cells produces the skin plaques of psoriasis. Ustekinumab reduces symptoms of psoriasis (inflammation and excessive production of skin cells) by attaching to IL-12 and IL-23, preventing them from binding and activating T-lymphocytes. In scientific studies, 59% to 73% of patients received an assessment of cleared or minimal psoriasis after 12 weeks of treatment. Ustekinumab was approved by the FDA in September 2009.



PREPARATIONS: Single use vials: 45 mg/0.5 ml and 90 mg /1 ml.

STORAGE: Ustekinumab should be refrigerated between 2 and 8 C (36 and 46 F). It should not be frozen and should be kept in its original carton to protect it from light until the time of administration.

PRESCRIBED FOR: Ustekinumab is used for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or medications that are absorbed into the blood stream (systemic therapy).

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index